Inflammatory Bowel Diseases
Author:
Keywords:
Science & Technology, Life Sciences & Biomedicine, Gastroenterology & Hepatology, inflammatory bowel disease, tissue remodeling genes, infliximab, mucosal expression, ULCERATIVE-COLITIS, CROHNS-DISEASE, AUTOIMMUNE-DISEASES, TISSUE INHIBITORS, METALLOPROTEINASES, ALPHA, BIOINFORMATICS, BIOMARKERS, PHENOTYPE, THERAPY, Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal, Antibodies, Monoclonal, Biopsy, Dose-Response Relationship, Drug, Female, Gene Expression Regulation, Humans, Immunohistochemistry, Inflammatory Bowel Diseases, Infliximab, Intercellular Signaling Peptides and Proteins, Intestinal Mucosa, Male, Matrix Metalloproteinases, Middle Aged, Prospective Studies, RNA, Real-Time Polymerase Chain Reaction, Treatment Outcome, Tumor Necrosis Factor-alpha, Young Adult, 1103 Clinical Sciences, 3202 Clinical sciences
Abstract:
Matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), a disintegrin and metalloprotease with thrombospondin motifs [ADAM(TS)s] and growth factors are involved in inflammation and tissue damage and repair, all occurring in inflammatory bowel disease (IBD). We studied the impact of anti-inflammatory therapy with infliximab on mucosal expression of these tissue remodeling genes in patients with IBD.